Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Gyre Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 41 | 35 | −6 |
| Shares | 8.03M | 7.73M | −300.1K (−3.7%) |
| Value | $14.2M | $3.90M | −$10.3M (−72.6%) |
New holders (3)
Institutions that held Gyre Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Group One Trading, L.P. | 48,560 | $24.0K | 0.00% |
| Lazard Asset Management LLC | 45,972 | $23.0K | 0.00% |
| Two Sigma Securities, LLC | 13,609 | $7.00K | 0.00% |
Sold out (9)
Institutions that held Gyre Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Madison Avenue Partners, LP | 1,006,300 | $1.79M |
| Essex Woodlands Management, Inc. | 78,622 | $140.0K |
| Susquehanna International Group, LLP | 25,367 | $45.0K |
| Black Diamond Financial, LLC | 18,000 | $32.0K |
| United Capital Financial Advisers, LLC | 10,000 | $18.0K |
| UBS Group AG | 7,682 | $14.0K |
| Acadian Asset Management LLC | 5,821 | $10.0K |
| Citigroup Inc | 500 | $1.00K |
| Blue Bell Private Wealth Management, LLC | 30 | $0 |